Dietetics blend
- Bifidobacterium breve – BR03 (DSM 16604)
- Streptococcus thermophilus – FP4 (DSM 18616)
Characteristics
Daily dosage in clinical study
1) 5 billion CFU + 5 billion CFU
Functionality
Immune response improving • Performance enhancing
Scientific support
Human clinical trials
1) Jäger R. et al. Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 Supplementation Attenuates Performance and Range-of-Motion Decrements Following Muscle Damaging Exercise. Nutrients. 2016 Oct 14;8(10). pii: E642.
2) Pane M. et al. Gut Microbiota, Probiotics, and Sport: From Clinical Evidence to Agonistic Performance. J Clin Gastroenterol, 2018;52:S46-S49.
In vitro studies
a) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
b) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
+ Internal data available upon request on CLA production and protection of gut epithelial barrier with BR03 (TEER)
